Document is current
Any future updates will be listed below
-
Authors
Thomas, Johanna
Rehman, Usama-Ur
Bresser, Helena
Grishina, Olga
Pfeifer, Dietmar
Sollier, Etienne
Döhner, Konstanze
Plass, Christoph
Becker, Heiko
Schmoor, Claudia
de Wit, Maike
Lübbert, Michael
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00867672 at ClinicalTrials.govDocuments that mention this clinical trial
Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype
https://doi.org/10.1186/s13148-024-01737-4
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (FOR2674 A02, FOR2674 A09, FOR2674 A05)
German Federal Ministry of Education and Research (01KG0913)
Universitätsklinikum Freiburg
- License Information
-
More Information
Article History
Received: 7 June 2024
Accepted: 29 August 2024
First Online: 11 September 2024
Declarations
:
: KD: Consultancy with honoraria: AbbVie, Janssen, Jazz, Novartis, Bristol Myers Squibb, Celgene; Clinical Research Funding to Institution: Novartis, AbbVie, Astellas, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Kronos Bio, Servier and ML: Advisory role with honoraria from AbbVie, Astex Pharmaceuticals, Imago BioSciences, Janssen, Otsuka, Syros. Research support (to institution) from Janssen; clinical research support with study drug from Cheplapharm. The DECIDER study was approved by the central ethics committee (University of Freiburg). The patient’s written consent to participate in this clinical trial was obtained before any study-specific procedures occurred.
